Bone marrow metastases. A review

Papac, Rose J.

doi:10.1002/1097-0142(19941101)74:9<2403::aid-cncr2820740904>3.0.co;2-f

Cited by 78 publications

(55 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible explanations were as follows. First, selection bias may have existed, although bone marrow examination was a standard diagnostic tool for detecting solid cancer with bone marrow metastases, and the invasive nature of the procedure may make patients or physicians reluctant to use it, especially for terminally ill patients who would not benefit from the confirmation of bone marrow metastases and for patients with certain cancer types for which the presence of leukoerythroblastosis is considered a surrogate diagnostic marker for bone marrow metastases (Burkhardt et al, 1981;Papac et al, 1994;Sar et al, 2001). A second explanation is the improved diagnostic modalities for detecting primary tumor, resulting in a decrease in the incidence of primary cancer of unknown origin from 29% to 8%.…”

Section: Discussionmentioning

confidence: 99%

“…Solid cancer with bone marrow metastases is a rare but lethal condition (Ringenberg et al, 1986;Wang et al, 1987;Papac RJ, 1994;Ozkalemkas et al, 2005;Kim et al, 2007;Kwon et al, 2011). Bone marrow biopsy has been the standard diagnostic modality for overt bone marrow metastases arising from solid cancers since 1958 when McFarland and Dameshek first described a simplified technique for bone marrow biopsy (McFarland et al, 1958).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases

Hung¹,

Chou²,

Chen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Solid cancers with bone marrow metastases are rare but lethal. This study aimed to identify clinical factors predictive of survival in adult patients with solid cancers and bone marrow metastases. Methods: A total of 83 patients were enrolled consecutively between January 1, 2000 and December 31, 2012. Bone marrow metastases were confirmed by biopsies. Patient clinical features and laboratory data were analyzed for associations. Results: The median age of the patients was 54 years (range, 23-88 years), and 58% were male. The 3 most common primary tumor locations were the stomach (32 patients, 39%), prostate (16 patients, 19%), and lungs (12 patients, 15%). The median overall survival was 49 days (range, 3-1423 days). Patients with Eastern Cooperative Oncology Group performance status 1, cancers of prostate origin, platelet counts over 50,000/ml, and undergoing antitumor therapies had a significantly better prognosis in the multivariate analysis. The median survival times were 173 and 33 days for patients with 2-3 more favorable parameters (n=24) and those with 0-1 (n=69), respectively (hazard ratio 0.30; 95% CI 0.17-0.52, p<0.001). Conclusions: Solid cancers with bone marrow metastases are dismal and incurable diseases. Understanding prognostic factors to these diseases helps medical personnel to provide appropriate treatments and better inform patients about outcomes. Antitumor therapies may improve outcomes in selected patient cohorts.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases

Hung¹,

Chou²,

Chen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…DCBM may also be referred to as 'symptomatic BM metastasis' (3) or 'BM carcinomatosis' (4); however, DCBM is considered to be the most appropriate term, as it suggests the diffuse infiltration of the BM by cancer cells and is associated with clinically important hematological disorders. Previous studies have reported that BM metastases from solid tumors are frequently detected in patients with breast, stomach, lung and prostate cancers (2,(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological characteristics of disseminated carcinomatosis of the bone marrow in breast cancer patients

Shinden

Sugimachi

Tanaka³

et al. 2017

mol clin onc

View full text Add to dashboard Cite

Abstract. Disseminated carcinomatosis of the bone marrow (DCBM) is characterized by diffuse infiltrative growth of tumor cells in the bone marrow and is associated with systemic hematological disorders. Bone marrow metastases from breast cancer are not rare, and they may lead to serious life-threatening conditions when there is an associated hematological disorder. Therefore, DCBM necessitates a definitive diagnosis and prompt systemic therapy. We herein present 4 such cases and a review of the previous relevant literature. Bone marrow biopsy is an effective method for diagnosing DCBM, and it may also be useful for selecting the optimal therapy. The malignant cells in the bone marrow biopsy specimens from all 4 patients were negative for progesterone receptor expression, and in 1 case, human epidermal growth factor receptor 2/neu expression was discordant between the primary tumor and the bone marrow metastases. Patients with DCBM often require granulocyte colony-stimulating factor and/or blood transfusions due to a DCBM-related hematological disorder. Although systemic chemotherapy for DCBM may temporarily exacerbate the need for hematological support, systemic chemotherapy may be effective for DCBM in breast cancer patients. In our experience, endocrine therapy has also been proven effective for DCBM. The aim of the present study was to review the clinical characteristics and the treatments used in 4 breast cancer patients with DCBM.

show abstract

“…In these cases, the histological findings such as immunohistochemical and other morphological parameters from the bone biopsy can assess the primary cancer diagnosis. The recognition of metastases in random biopsies is a challenge to haematologists and pathologists alike [2,3].…”

Section: Introductionmentioning

confidence: 99%

Bone Marrow Metastases as an Initial Presentation of Gastrointestinal Adenocarcinoma: A Case Report

Molina-Arrebola¹

2017

CMR

View full text Add to dashboard Cite

Bone marrow metastases as the initial presentation of a solid tumour are uncommon, especially if the primary neoplasm site cannot be identified during the diagnosis presentation despite laboratory testing and imaging techniques. In these situations, bone marrow examination can lead to a final diagnosis of the primary malignancy. We report an unusual case of osteoblastic metastases from an unknown primary site -this was because no relevant lesions were found from either imaging or endoscopic examination. The patient was sent for a bone marrow biopsy, revealing a morphology replaced by glandular structures and an immunohistochemistry consistent with a gastrointestinal origin. Bone marrow examination was the clue to the final diagnosis and led to specific treatment.

show abstract

Bone marrow metastases. A review

Cited by 78 publications

References 72 publications

Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases

Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases

Clinicopathological characteristics of disseminated carcinomatosis of the bone marrow in breast cancer patients

Bone Marrow Metastases as an Initial Presentation of Gastrointestinal Adenocarcinoma: A Case Report

Contact Info

Product

Resources

About